Monopar Therapeutics (MNPR) news
Recent news
Monopar Therapeutics Inc.: Barclays raises target price to $145 from $128
Barclays analyst Etzer Darout has raised the price target for Monopar Therapeutics Inc. (MNPR) to $145 from $128, while maintaining a Buy rating on the stock. This adjustment follows recent updates to the company’s financial model and ongoing developments in its clinical pipeline, particularly for…
AInvest Wire · Sep 11, 2026Monopar Therapeutics reports second quarter 2026 financial results and provides business updates
AInvest Wire · Aug 12, 2026Monopar Therapeutics Inc: Piper Sandler raises target price to $123 from $101
AInvest Wire · Jul 22, 2026Monopar Therapeutics Inc.: H.C. Wainwright raises target price to $125 from $105
H.C. Wainwright & Co. has revised its price target for Monopar Therapeutics Inc. (NASDAQ: MNPR), raising it to $125 from $105, while maintaining an "Outperform" rating for the stock. The adjustment reflects the firm’s updated assessment of the company’s clinical and regulatory developments,…
AInvest Wire · Jul 22, 2026Monopar's ALXN1840 targets Wilson disease in FDA bid
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.